Your browser doesn't support javascript.
loading
Development, optimization and characterization of cisplatin loaded cubosomes for human lung carcinoma.
Umar, Hassaan; Wahab, Habibah A; Ahmed, Nadeem; Fujimura, Nao Akusa; Amjad, Muhammad Wahab; Bukhari, Syed Nasir Abbas; Ahmad, Waqas.
Afiliación
  • Umar H; School of Pharmaceutical Science, Universiti Sains Malaysia, Minden, Malaysia.
  • Wahab HA; School of Pharmaceutical Science, Universiti Sains Malaysia, Minden, Malaysia.
  • Ahmed N; CEMB, Lahore, Pakistan.
  • Fujimura NA; CEMB, Lahore, Pakistan.
  • Amjad MW; Center for Ultrasound Molecular Imaging and Therapeutics, Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, USA.
  • Bukhari SNA; Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Aljouf, Saudi Arabia.
  • Ahmad W; School of Pharmaceutical Science, Universiti Sains Malaysia, Minden, Malaysia.
Drug Dev Ind Pharm ; : 1-14, 2024 Mar 20.
Article en En | MEDLINE | ID: mdl-38451066
ABSTRACT

OBJECTIVES:

This study aimed to develop, optimize and evaluate glyceryl monooleate (GMO) based cubosomes as a drug delivery system containing cisplatin for treatment of human lung carcinoma.

SIGNIFICANCE:

The significance of this research was to successfully incorporate slightly water soluble and potent anticancer drug (cisplatin) into cubosomes, which provide slow and sustained release of drug for longer period of time.

METHODS:

The delivery system was developed through top-down approach by melting GMO and poloxamer 407 (P407) at 70 °C and then drop-wise addition of warm deionized water (70 °C) containing cisplatin. The formulation then exposed to probe sonicator for about 2 min. A randomized regular two level full factorial design with help of Design Expert was used for optimization of blank cubosomal formulations. Cisplatin loaded cubosomes were then subjected to physico-chemical characterization.

RESULTS:

The characterization of the formulation revealed that it had a sufficient surface charge of -9.56 ± 1.33 mV, 168.25 ± 5.73 nm particle size, and 60.64 ± 0.11% encapsulation efficiency. The in vitro release of cisplatin from the cubosomes at pH 7.4 was observed to be sustained, with 94.5% of the drug being released in 30 h. In contrast, 99% of cisplatin was released from the drug solution in just 1.5 h. In vitro cytotoxicity assay was conducted on the human lung carcinoma NCI-H226 cell line, the cytotoxicity of cisplatin-loaded cubosomes was relative to that of pure cisplatin solution, while blank (without cisplatin) cubosomes were nontoxic.

CONCLUSIONS:

The obtained results demonstrated the successful development of cubosomes for sustained delivery of cisplatin.
Cubosomes were prepared, optimized, and evaluated for cisplatin delivery.A randomized regular two level full factorial design was constructed to optimize blank cubosomes.Blank cubosomes consisted of GMO as the lipid and P407 as an emulsifying agent.In vitro release studies demonstrated sustained release of cisplatin from cubosomes at pH 7.4.Cytotoxicity assay on human lung carcinoma cell line NCI-H226 showed similar cytotoxicity between cisplatin-loaded cubosomes and pure cisplatin solution while blank cubosomes exhibited no toxicity.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Drug Dev Ind Pharm Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Drug Dev Ind Pharm Año: 2024 Tipo del documento: Article